感染科用药专栏
YANG Daofeng;WU Liang;ZHANG Bei;TIAN Deying
2005, 24(4): 0-0.
ObjectiveTo assess the therapeutic efficiency and safety rate of rifaximin in the treatment of acute bacterial infection of the intestine. MethodsA multicentre, random, doubleblind and doubledummy parallel control protocol was employed in the trial. 211 patients with acute bacterial infection of the intestine were randomly divided into the treatment group and control group. 107 cases in the treatment group were given each 0.2 g of rifaximin, PO, q.6 h. and 1 ciprofloxacin dummy tablet, PO,b.i.d.. 104 cases in the control group were given each 0.25 g of ciprofloxacin, PO, b.i.d. and 2 rifaximin dummy tablets,q.6 h.. The course of treatment in both groups lasted 5 days.The therapeutic efficiency of the 2 drugs was appraised. ResultsThe overall effective rates in patients of the treatment group and control group were 94.4% and 96.1%,respectively, while the corresponding cure rates were 75.7% and 84.6%,respectively. The bacteria elimination rates were 96.2% and 96.3%,respectively, and the incidences of adverse reactions were 2.8% and 2.9%, respectively. Differences between the two groups were not statistically significant(P>0.05).ConclusionRifaximin was shown to be effective and safe in the treatment of acute bacterial infection of the intestine. Its adverse reactions were rare and mild. The therapeutic efficiency and safety rate of rifaximin were similar to those of ciprofloxacin.